Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization277 mentions
- NVIDIAorganization265 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
ATR 1072
product3 mentionslast seen Nov 2, 2026
RNA therapeutic for PRKAG2 syndrome with FDA IND clearance, being advanced in the Corventis Phase 1/2 clinical trial.
Relationships 8
- Atrium Therapeutics, Inc.developsATR 107299% confidence3 sources
- ATR 1072applies toPRKAG2 syndrome treatment99% confidence2 sources
- ATR 1072applies toPRKAG2 cardiomyopathy93% confidence1 source
- ATR 1072depends onPRKAG2 mRNA93% confidence1 source
- ATR 1072depends onsmall interfering RNA90% confidence1 source
- ATR 1072composed ofsmall interfering RNA90% confidence1 source
- ATR 1072composed ofmonoclonal antibody85% confidence1 source
- ATR 1072composed ofoligonucleotide85% confidence1 source
Relationship
Atrium Therapeutics, Inc.developsATR 1072
99% confidence3 supporting mentions
Either name opens that entity’s relationships.
Sources 3
- filingSEC EDGARNov 2, 2026Atrium Therapeutics, Inc. 8-K: Item 7.01: Regulation FD Disclosure; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart
- filingSEC EDGAROct 27, 2026Atrium Therapeutics, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Atrium Therapeutics, Inc. (the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today announced that the first patient has been dosed in the Phase 1/2 Corventis clinical trial evaluating ATR 1072, its lead investigational therapy
- filingSEC EDGAROct 8, 2026Atrium Therapeutics, Inc. 8-K: Item 1.01: Entry into a Material Definitive Agreement; Item 3.02: Unregistered Sales of Equity Securities; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
FDA's (FDA) clearance of its Investigational New Drug (IND) application for ATR 1072